Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03552289 · ClinicalTrials.gov registry record · NA
Cook Enforcer Post-Market Study
A NA study, sponsored by Cook Research Incorporated.
- Completed
- Registry status
- NA
- Development phase
- 211
- Enrollment target
NCT03552289: Completed NA study, sponsored by Cook Research Incorporated.
NCT03552289 is a NA study that has completed, run by Cook Research Incorporated. The registered enrollment target is 211 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03552289, a NA study, has completed, sponsored by Cook Research Incorporated.
- COMPLETED
- Registry status
- NA
- Development phase
- 211 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the performance of the Cook Advance® Enforcer™ 35 Focal-Force PTA Balloon Catheter (or Enforcer balloon) in treating narrowed blood vessels compared to treatment with a conventional angioplasty balloon.
Primary Outcome
Percentage of lesions requiring adjunctive treatment immediately following the initial treatment with the Enforcer or conventional angioplasty balloon
Interventions
- DEVICE Cook Advance® Enforcer 35 Focal-Force Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter
- DEVICE Conventional angioplasty balloon catheters
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 211 participants |
| Start Date | 2018-08-07 |
| Est. Completion | 2019-08-27 |
| Phase | NA |
What the finished NCT03552289 record still lists
NCT03552289 is an interventional study that assigns participants to a tested intervention. The registered 211 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Cook Advance® Enforcer 35 Focal-Force Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter is the first listed.
NCT03552289 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03552289 about?
NCT03552289 is a clinical study titled "Cook Enforcer Post-Market Study". The purpose of this study is to evaluate the performance of the Cook Advance® Enforcer™ 35 Focal-Force PTA Balloon Catheter (or Enforcer balloon) in treating narrowed blood vessels compared to treatment with a conventional angioplasty balloon.
What is the current status of trial NCT03552289?
This trial is currently completed. It is a NA study. The enrollment target is 211 participants. The study started on 2018-08-07. Estimated completion is 2019-08-27.
What interventions are being tested in trial NCT03552289?
The interventions under investigation include: Cook Advance® Enforcer 35 Focal-Force Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (DEVICE), Conventional angioplasty balloon catheters (DEVICE).
Who is sponsoring clinical trial NCT03552289?
This trial is sponsored by Cook Research Incorporated, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03552289's enrollment target sits among peer trials
211 490th of 2000 higher than 1,511 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06698796 · 211 participants · Phase 3
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
- NCT04228978 · 212 participants · NA
Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss
- NCT04725721 · 212 participants · NA
Testing FIRST in Youth Outpatient Psychotherapy
- NCT06257576 · 212 participants · Phase 3
Function of Tamsulosin in Older Males Undergoing Surgery with Indwelling Catheter
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI